Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
RBM45 CRISPR/Cas9 KO Plasmid (h): sc-406889
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- RBM45 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the RBM45 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: RBM45 Antibody (A-2): sc-515495
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
RBM45 CRISPR/Cas9 KO Plasmid (h) | sc-406889 | 20 µg | $397.00 |
Overview
RBM45 (RNA binding motif protein 45) is a conserved RNA-binding protein implicated in post-transcriptional gene regulation through interactions with pre-mRNA and RNA processing complexes. It has been linked to control of RNA splicing, transcript stability, and stress-responsive ribonucleoprotein assembly, processes that shape neuronal and glial gene-expression programs. RBM45 is frequently studied in the context of neurodegeneration and RNA dysmetabolism, including its association with pathogenic protein aggregation and altered RNA granule dynamics. Perturbation of RBM45 function can therefore be used to interrogate pathways connecting RNA processing, cellular stress responses, and proteostasis.
RBM45 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the RBM45 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the RBM45 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the RBM45 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish RBM45 protein expression.
This CRISPR knockout system enables efficient generation of RBM45-deficient cell models for investigation of RBM45 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting RBM45 exon(s) critical for RBM45 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple RBM45 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by RBM45 CRISPR/Cas9 KO Plasmid (h) and RBM45 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the RBM45 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by RBM45 HDR Plasmid (h) and RBM45 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by RBM45 homology arms to support homology-directed repair at defined RBM45 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.